Target intelligence / Profile preview

P-glycoprotein 1 (MDR1)

Target
MDR1
Molecular classification
Transporter, ATP-binding cassette transporter, ABC transporter
01

Overview

P-glycoprotein 1 (P-gp), encoded by the ABCB1 (MDR1) gene, is a well-characterized ATP-dependent efflux transporter. It is widely expressed in physiological barrier tissues, including the intestinal epithelium, the canalicular membrane of hepatocytes, the proximal tubules of the kidney, and the capillary endothelial cells of the blood-brain barrier. In these tissues, P-gp functions as a protective mechanism, pumping a broad range of structurally diverse xenobiotics, toxins, and therapeutic drugs out of cells and back into excretory pathways or the bloodstream, thereby limiting their systemic absorption and tissue penetration. In pathological contexts, particularly oncology, the overexpression of P-gp in cancer cells is a primary driver of multidrug resistance (MDR). By actively extruding chemotherapeutic agents such as anthracyclines, taxanes, and vinca alkaloids, P-gp significantly reduces intracellular drug accumulation and compromises treatment efficacy. Consequently, P-gp has been a major target for the development of chemosensitizers and efflux inhibitors. Additionally, genetic polymorphisms in the ABCB1 gene, such as the C3435T variant, are critical pharmacogenomic biomarkers that influence drug bioavailability, efficacy, and the risk of adverse drug-drug interactions.

Other names
Multidrug resistance protein 1ATP-binding cassette sub-family B member 1ATP-dependent translocase ABCB1P-gpPGY1CD243Colchicin sensitivityDoxorubicin resistancePhospholipid transporter ABCB1
02

Mechanism of action

Inhibition of ATP-dependent efflux, competitive substrate transport, and induction of transporter expression.

03

Biological functions

TransportDrug effluxXenobiotic clearanceLipid translocationBlood-brain barrier maintenanceOther
04

Disease associations

CancerInflammationNeurodegenerative diseaseOther
05

Safety considerations

Drug-drug interactions (DDIs)Increased blood-brain barrier permeability leading to neurotoxicityAltered pharmacokinetics of co-administered drugsSystemic toxicity of chemotherapeutic agentsIncomplete dominance of MDR1 mutations in veterinary medicine (e.g., ivermectin sensitivity in herding dogs)
06

Interacting drugs

13 more in the full profile.

07

Biomarkers

ABCB1 gene expressionABCB1 polymorphisms (e.g., C3435T / rs1045642)P-glycoprotein expression levelCalcein AM efflux activityRhodamine 123 efflux activity

Beyond the preview

Go deeper on P-glycoprotein 1 (MDR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-glycoprotein 1 (MDR1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call